These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 7049347)

  • 1. Comparison of induction chemotherapies for metastatic breast cancer. An Eastern Cooperative Oncology Group Trial.
    Tormey DC; Gelman R; Band PR; Sears M; Rosenthal SN; DeWys W; Perlia C; Rice MA
    Cancer; 1982 Oct; 50(7):1235-44. PubMed ID: 7049347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An Eastern Cooperative Oncology Group trial.
    Tormey DC; Gray R; Gilchrist K; Grage T; Carbone PP; Wolter J; Woll JE; Cummings FJ
    Cancer; 1990 Jan; 65(2):200-6. PubMed ID: 2403834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy of advanced breast cancer: a randomized trial of vincristine, Adriamycin, and cyclophosphamide (VAC) versus cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP).
    Carmo-Pereira J; Costa FO; Henriques E
    Cancer; 1981 Oct; 48(7):1517-21. PubMed ID: 7026020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II trial of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisolone rapidly alternating with doxorubicin and vincristine (CMFP/AV) in advanced breast cancer.
    Rischin D; Bishop JF; Olver IN; Laidlaw CR; Zimet A; Jeal P; Dipell JF
    Am J Clin Oncol; 1992 Oct; 15(5):392-4. PubMed ID: 1524039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of CAF versus CMFP in metastatic breast cancer: analysis of prognostic factors.
    Cummings FJ; Gelman R; Horton J
    J Clin Oncol; 1985 Jul; 3(7):932-40. PubMed ID: 3894587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized clinical trial of CFP versus CMFP in women with metastatic breast cancer.
    Marschke RF; Ingle JN; Schaid DJ; Krook JE; Mailliard JA; Cullinan SA; Pfeifle DM; Votava HJ; Ebbert LP; Windschitl HE
    Cancer; 1989 May; 63(10):1931-7. PubMed ID: 2649221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low dose chemotherapy of metastatic breast cancer with cyclophosphamide, adriamycin, methotrexate, 5-fluorouracil (CAMF) versus sequential cyclophosphamide, methotrexate, 5-fluorouracil (CMF) and adriamycin.
    Creech RH; Catalano RB; Harris DT; Engstrom PF; Grotzinger PJ
    Cancer; 1979 Jan; 43(1):51-9. PubMed ID: 367574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective evaluation of chemohormonal therapy remission maintenance in advanced breast cancer.
    Tormey DC; Gelman R; Band PR; Sears M; Bauer M; Arseneau JC; Falkson G
    Breast Cancer Res Treat; 1981; 1(2):111-9. PubMed ID: 7348567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postoperative chemotherapy and chemohormonal therapy in women with node-positive breast cancer.
    Tormey DC; Gray R; Taylor SG; Knuiman M; Olson JE; Cummings FJ
    NCI Monogr; 1986; (1):75-80. PubMed ID: 3534593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer: preliminary results. Taxol Investigational Trials Group, Australia/New Zealand.
    Bishop JF; Dewar J; Toner G; Tattersall MH; Olver I; Ackland S; Kennedy I; Goldstein D; Gurney H; Walpole E; Levi J; Stephenson J
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-5-S17-9. PubMed ID: 9374084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. Cancer and Leukemia Group B.
    Aisner J; Weinberg V; Perloff M; Weiss R; Perry M; Korzun A; Ginsberg S; Holland JF
    J Clin Oncol; 1987 Oct; 5(10):1523-33. PubMed ID: 3655855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Six-year results of the Eastern Cooperative Oncology Group trial of observation versus CMFP versus CMFPT in postmenopausal patients with node-positive breast cancer.
    Taylor SG; Knuiman MW; Sleeper LA; Olson JE; Tormey DC; Gilchrist KW; Falkson G; Rosenthal SN; Carbone PP; Cummings FJ
    J Clin Oncol; 1989 Jul; 7(7):879-89. PubMed ID: 2661734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer. International (Ludwig) Breast Cancer Study Group.
    Marini G; Murray S; Goldhirsch A; Gelber RD; Castiglione-Gertsch M; Price KN; Tattersall MH; Rudenstam CM; Collins J; Lindtner J; Cavalli F; Cortés-Funes H; Gudgeon A; Forbes JF; Galligioni E; Coates AS; Senn HJ
    Ann Oncol; 1996 Mar; 7(3):245-50. PubMed ID: 8740787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: three-year results of an Eastern Cooperative Oncology Group study.
    Taylor SG; Kalish LA; Olson JE; Cummings F; Bennett JM; Falkson G; Tormey DC; Carbone PP
    J Clin Oncol; 1985 Feb; 3(2):144-54. PubMed ID: 3881561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial of five and three drug chemotherapy and chemoimmunotherapy in women with operable node positive breast cancer.
    Tormey DC; Weinberg VE; Holland JF; Weiss RB; Glidewell OJ; Perloff M; Falkson G; Falkson HC; Henry PH; Leone LA
    J Clin Oncol; 1983 Feb; 1(2):138-45. PubMed ID: 6366133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adriamycin combinations in advanced breast cancer. A Southwest Oncology Group Study.
    Tranum BL; McDonald B; Thigpen T; Vaughn C; Wilson H; Maloney T; Costanzi J; Bickers J; el Mawli NG; Palmer R; Hoogstraten B; Heilburn L; Rasmusen S
    Cancer; 1982 Mar; 49(5):835-9. PubMed ID: 7037152
    [No Abstract]   [Full Text] [Related]  

  • 17. Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer. A prospective randomized study.
    Cocconi G; De Lisi V; Boni C; Mori P; Malacarne P; Amadori D; Giovanelli E
    Cancer; 1983 Feb; 51(4):581-8. PubMed ID: 6336981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer: a randomized trial.
    Muss HB; White DR; Richards F; Cooper MR; Stuart JJ; Jackson DV; Rhyne L; Spurr CL
    Cancer; 1978 Nov; 42(5):2141-8. PubMed ID: 363253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment.
    Falkson G; Gelman RS; Pandya KJ; Osborne CK; Tormey D; Cummings FJ; Sledge GW; Abeloff MD
    J Clin Oncol; 1998 May; 16(5):1669-76. PubMed ID: 9586877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective evaluation of rotating chemotherapy in advanced breast cancer. An Eastern Cooperative Oncology Group Trial.
    Tormey D; Gelman R; Falkson G
    Am J Clin Oncol; 1983 Feb; 6(1):1-18. PubMed ID: 6340458
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.